Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/26—Glucagons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
  • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/605—Glucagons
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present disclosure relates generally to the field of treatments for metabolic disorders and fatty liver diseases. More specifically, the present disclosure relates to the field of formulations of small molecule drugs for the treatment of diseases including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD).
• NASH non-alcoholic steatohepatitis
• NAFLD non-alcoholic fatty liver disease
• Incretin peptides glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are metabolic hormones.
• GIP and GLP-1 are both secreted within minutes of nutrient ingestion and facilitate the rapid disposal of ingested nutrients. Both peptides share common actions on islet ⁇ -cells acting through structurally distinct yet related receptors. Incretin-receptor activation leads to glucose-dependent insulin secretion, induction of ⁇ -cell proliferation, and enhanced resistance to apoptosis. GIP also promotes energy storage via direct actions on adipose tissue. In contrast, GLP-1 exerts glucoregulatory actions via slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion. GLP-1 also promotes satiety and sustained GLP-1–receptor activation is associated with weight loss in both preclinical and clinical studies.
• Non-alcoholic fatty liver disease is the hepatic manifestation of metabolic syndrome and is the most common cause of chronic liver disease. NAFLD may progress to liver inflammation, fibrosis, cirrhosis and even hepatocellular carcinoma.
• GIP/GLP-1 dual receptor agonists have been developed for treating NAFLD, non-alcoholic steatohepatitis (NASH), diabetes, obesity, and other diseases.
• NASH non-alcoholic steatohepatitis
• diabetes obesity
• other diseases the use of GIP/GLP- 1 dual receptor agonists is associated with nausea, vomiting, and/or diarrhea.
• clinical trials of a GIP/GLP1 dual receptor agonist compound found that tolerability at high doses was limited by gastrointestinal adverse events.
• the dose limitation associated with gastrointestinal adverse events may prevent dosing to the desired effective dose, may compromise patient compliance with treatment, and may limit the effectiveness of the treatment regimen. Therefore, a need exists for formulations of novel GIP/GLP1 dual agonist compounds that can be used to treat fatty liver diseases and other diseases and disorders.
• Other embodiments disclosed herein include the pharmaceutically acceptable carrier that comprises at least 10% by weight of propylene glycol.
• Other embodiments disclosed herein include the pharmaceutically acceptable diluent that is a pH buffer. In some embodiments, the pharmaceutically acceptable diluent is present in the formulation at a weight percentage of equal to or more than about 20%.
• Other embodiments disclosed herein include a method of preventing, treating, or ameliorating one or more fatty liver diseases in a subject, by administering the pharmaceutical formulations disclosed herein to a subject in need thereof.
• the fatty liver diseases include but are not limited to steatosis, non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD).
• inventions disclosed herein include a method of preventing, treating, or ameliorating one or disease or disorders in a subject, by administering the pharmaceutical formulations disclosed herein to a subject in need thereof.
• said disease or disorder is liver fibrosis, renal fibrosis, biliary fibrosis, pancreatic fibrosis, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis, primary biliary cirrhosis, or idiopathic fibrosis.
• said disease or disorder is a metabolic disorder or a metabolic syndrome.
• said disease or disorder is atherosclerosis, diabetes, hyperglycemic diabetes, type 2 diabetes mellitus, dyslipidemia, hypercholesterolemia, hyperlipidemia, hypertension, hypoglycemia, obesity, or prader-willi syndrome.
• pharmaceutical formulations are provided for administration to a subject in need thereof.
• Various embodiments of these pharmaceutical formulations include a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, a pharmaceutically acceptable diluent, and any combination of the foregoing.
• Some embodiments of the pharmaceutical formulations include a therapeutically effective dosage of a compound, or a pharmaceutically acceptable salt thereof, as described elsewhere herein.
• the pharmaceutical formulations are administered for the prevention, treatment, or amelioration of one or more fatty liver diseases in the subject.
• the fatty liver diseases include but are not limited to steatosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD).
• the pharmaceutical formulations include compounds that are non-macrocyclic functionalized peptides that act as GIP/GLP-1 dual receptor agonists.
• Various embodiments of these compounds include compounds having the structure of formula I as described above or pharmaceutically acceptable salts thereof.
• the structure of formula I encompasses all stereoisomers and racemic mixtures, including the following structure and mixtures thereof:
• Some embodiments of compounds of formula I include compounds having the structure of formula I-a: or pharmaceutically acceptable salts thereof.
• Z 1 is selected from hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 1-6 alkoxy, C 3-10 cycloalkyl and C 6-10 aryl; and X and Y each are –OR 4 .
• Z 1 is selected from hydrogen, haloC 1-6 alkoxy and C 1-6 alkoxy; and each R 4 may be independently selected from hydrogen, C 6-10 aryloxy and C 6-10 aryl alkoxy.
• Z 1 is hydrogen and each R 4 may be independently hydrogen or C 6-10 aryl alkoxy.
• each R 4 is hydrogen.
• Z 1 is hydrogen and each R 4 is hydrogen.
• Some embodiments of compounds of formula I include compounds having the structure of formula I-b: or pharmaceutically acceptable salts thereof.
• Z 2 is selected from hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, C 1-6 alkoxy, C 3-10 cycloalkyl and C 6-10 aryl; and X and Y each are –OR 4 .
• Z 2 is selected from hydrogen, haloC 1-6 alkoxy and C 1-6 alkoxy; and each R 4 may be independently selected from hydrogen, C 6-10 aryloxy and C 6-10 aryl alkoxy.
• Z 2 is hydrogen and each R 4 may be independently hydrogen or C 6-10 aryl alkoxy.
• each R 4 is hydrogen.
• Z 2 is hydrogen and each R 4 is hydrogen.
• Some embodiments of compounds of formula I include compounds having the structure of formula I-c:
• each R 4 may be independently selected from hydrogen, C6- 10 aryloxy and C 6-10 aryl alkoxy.
• each R 4 is hydrogen.
• Some embodiments include a compound having the structure selected from the group consisting of:
• Some embodiments include a compound wherein “*” indicates a chiral carbon with “S” configuration. [0030] Some embodiments include a compound wherein “*” indicates a chiral carbon with “R” configuration. [0031] Where the compounds disclosed herein have at least one chiral center, they may exist as individual enantiomers and diastereomers or as mixtures of such isomers, including racemates. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, all such isomers and mixtures thereof are included in the scope of the compounds disclosed herein.
• compounds disclosed herein may exist in one or more crystalline or amorphous forms. Unless otherwise indicated, all such forms are included in the scope of the compounds disclosed herein including any polymorphic forms.
• some of the compounds disclosed herein may form solvates with water (i.e., hydrates) or common organic solvents. Unless otherwise indicated, such solvates are included in the scope of the compounds disclosed herein.
• solvates with water (i.e., hydrates) or common organic solvents. Unless otherwise indicated, such solvates are included in the scope of the compounds disclosed herein.
• the pharmaceutical formulations include at least one pharmaceutically acceptable carrier.
• pharmaceutically acceptable carrier as used herein, is given its ordinary meaning to those skilled in the art.
• the pharmaceutically acceptable carrier comprises propylene glycol.
• the pharmaceutically acceptable carrier is present in the formulation at a weight percentage of equal to or more than about: 1%, 5%, 10%, 15%, 20%, 25%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38% 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 60%, 70%, 80%, 90%, 95%, or ranges including and/or spanning the aforementioned values.
• the pharmaceutically acceptable carrier is present in the formulation at a weight percentage from about 10% to 90% by weight.
• the pharmaceutically acceptable carrier is present in the formulation at a weight percentage from about 30% to 50%.
• the pharmaceutical formulations may include at least one pharmaceutically acceptable diluent.
• pharmaceutically acceptable diluent as used herein, is given its ordinary meaning to those skilled in the art.
• the pharmaceutically acceptable diluent comprises saline or sterilized water.
• the pharmaceutically acceptable diluent comprises a pH buffer.
• the pharmaceutically acceptable diluent is a pH buffer selected from tartrate, citrate, acetate, 2-(N-morpholino)ethanesulfonic acid (MES), piperazine-N,N’-bis(2- ethanesulfonic acid (PIPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-[[1,3- dihydroxy-2-(hydroxymethyl)propan-2-yl] amino] ethanesulfonic acid (TES), 4-(2- hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-[N-tris(hydroxymethyl) methylamino]-2-hydroxypropanesulfonic acid (TAPSO), N-[tris(hydroxymethyl)methyl] glycine (Tricine), tris(hydroxymethyl )aminomethane (Tris), 2-(bis(2-hydroxyethyl)amino) acetic acid (Bicine), tris(hydroxymethyl)
• MES
• the pharmaceutically acceptable diluent has a pH of about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or ranges including and/or spanning the aforementioned values. In some embodiments, the pharmaceutically acceptable diluent has a pH from about 3 to 7. In some embodiments, the pharmaceutically acceptable diluent has a pH from about 4 to 6.8.
• the concentration of the pharmaceutically acceptable diluent is about: 0.01 mM, 0.05 mM, 0.1 mM, 0.5 mM, 1 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 70 mM, 100 mM, 200 mM, 500 mM, 1000 mM, or ranges including and/or spanning the aforementioned values.
• the concentration of the pharmaceutically acceptable diluent is from about 1 to 50 mM. In some embodiments, the concentration of the pharmaceutically acceptable diluent is from about 8 to 12 mM. In some embodiments, the pharmaceutically acceptable diluent is present in the formulation at a weight percentage of equal to or more than about: 1%, 5%, 10%, 20%, 30%, 40%, 50%, 53%, 55%, 57%, 59%, 60%, 61%, 63%, 65%, 67%, 70%, 75%, 80%, 90%, 95%, or ranges including and/or spanning the aforementioned values. In some embodiments, the pharmaceutically acceptable diluent is present in the formulation at a weight percentage from about 20% to 95% by weight.
• the pharmaceutically acceptable diluent is present in the formulation at a weight percentage from about 50% to 70%.
• the pharmaceutical formulations comprise propylene glycol and a pH buffer.
• the pH buffer comprises tartrate in a suitable solvent (e.g., water).
• the pH buffer comprises citrate in a suitable solvent (e.g., water).
• the pH buffer comprises acetate in a suitable solvent (e.g., water).
• the pH buffer comprises 2-(N- morpholino)ethanesulfonic acid (MES) in a suitable solvent (e.g., water).
• MES 2-(N- morpholino)ethanesulfonic acid
• the pH buffer comprises piperazine-N,N’-bis(2-ethanesulfonic acid (PIPES) in a suitable solvent (e.g., water).
• PPES piperazine-N,N’-bis(2-ethanesulfonic acid
• a suitable solvent e.g., water
• the pH buffer has a pH of about: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or ranges including and/or spanning the aforementioned values.
• the pH buffer has a pH from about 3 to 7.
• the pH buffer has a pH from about 4 to 6.8.
• the pH buffer has a pH from about 5 to 6.8.
• the concentration of the pH buffer is about: 0.01 mM, 0.05 mM, 0.1 mM, 0.5 mM, 1 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 20 mM, 25 mM, 30 mM, 40 mM, 50 mM, 70 mM, 100 mM, 200 mM, 500 mM, 1000 mM, or ranges including and/or spanning the aforementioned values. In some embodiments, the concentration of the pH buffer is from about 1 to 50 mM.
• the concentration of the pH buffer is from about 8 to 12 mM.
• propylene glycol is present in the formulation at a weight percentage of equal to or more than about 10% and the pH buffer is present in the formulation at a weight percentage of equal to or more than about 20%.
• the propylene glycol is present in the formulation at a weight percentage from about 10% to 90%.
• the propylene glycol is present in the formulation at a weight percentage from about 20% to 70%.
• the propylene glycol is present in the formulation at a weight percentage from about 30% to 50%.
• the pH buffer is present in the formulation at a weight percentage from about 20% to 95%.
• the pH buffer is present in the formulation at a weight percentage from about 30% to 80%. In some embodiments, pH buffer is present in the formulation at a weight percentage from about 50% to 70%. In some embodiments, the pH of the formulation is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or ranges including and/or spanning the aforementioned values. In some embodiments, the formulation has a pH from about 3 to 7. In some embodiments, the formulation has a pH from about 4 to 6.8. In some embodiments, the formulation has a pH from about 5 to 6.8. [0036] The pharmaceutical formulations include a therapeutically effective dosage.
• the term “therapeutically effective dosage,” as used herein, is dependent on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician.
• the therapeutically effective dosage may be a daily dosage from about 0.0125 mg/kg to about 120 mg/kg or more of body weight, from about 0.025 mg/kg or less to about 70 mg/kg, from about 0.05 mg/kg to about 50 mg/kg of body weight, or from about 0.075 mg/kg to about 10 mg/kg of body weight.
• the dosage range would be from about 0.88 mg per day to about 8000 mg per day, from about 1.8 mg per day or less to about 7000 mg per day or more, from about 3.6 mg per day to about 6000 mg per day, from about 5.3 mg per day to about 5000 mg per day, or from about 11 mg to about 3000 mg per day.
• the therapeutically effective dosage is from about 0.001 mg/kg, 0.005 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.15 mg/kg, 0.16 mg/kg, 0.18 mg/kg, 0.19 mg/kg, 0.2 mg/kg, 0.21 mg/kg, 0.22 mg/kg, 0.24 mg/kg, 0.25 mg/kg, 0.26 mg/kg, 0.28 mg/kg, 0.3 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, 25 mg/kg, 50 mg/kg, 100v, 200 mg/kg, 500 mg/kg, or ranges including and/or spanning the aforementioned values.
• the therapeutically effective dosage is from about 0.01 mg/kg to about 5 mg/kg. In some embodiments, the therapeutically effective dosage is from about 0.05 mg/kg to about 1 mg/kg. In some embodiments, the therapeutically effective dosage is from about 0.15 mg/kg to about 0.25 mg/kg. [0037]
• the pharmaceutical formulations have a half life in the blood of the subject when they are administered.
• the half life is equal to or greater than about: 5 h, 10 h, 20 h, 40 h, 60 h, 80 h, 90 h, 100 h, 110 h, 115 h, 118 h, 120 h, 122 h, 125 h, 128 h, 130 h, 150 h, 180 h, 200 h, 250 h, 300 h, 500 h, or ranges including and/or spanning the aforementioned values.
• the half life is from about 40 h to 300 h. In some embodiments, the half life is from about 60 h to 150 h.
• the pharmaceutical formulations can be administered with a route of administration including, but not limited to, enteral, intravenous, oral, intraarticular, intramuscular, subcutaneous, intraperitoneal, epidural, intranasal, topical, intrapulmonary, vaginal, rectal, transdermal, and transmucosal.
• the route of administration selected from the group consisting of enteral, intravenous, oral, intraarticular, intramuscular, subcutaneous, intraperitoneal, epidural, transdermal, and transmucosal.
• the pharmaceutical formulations are administered subcutaneously.
• the pharmaceutical formulations are administered intravenously.
• the pharmaceutical formulations are administered orally.
• the pharmaceutical formulations can be provided in a dosage form.
• the dosage form is selected from a solid form and a liquid form.
• the solid dosage forms include tablets, capsules, granules and bulk powders.
• the liquid dosage forms include solutions, emulsions, and suspensions.
• the dosage form is a solid form.
• the dosage form is a liquid form.
• the pharmaceutical formulations include at least one pharmaceutically-acceptable excipient(s).
• pharmaceutically acceptable excipient includes but is not limited to solvents, dispersants, coatings, antimicrobial bacterial agents, adjuvants, isotonic and absorption delaying agents and the like.
• the pharmaceutically-acceptable excipients include sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers and surfactants, such as the TWEENS; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives such as benzalkon
• the pharmaceutically-acceptable excipient(s) are selected based on the route of administration and can include solid or liquid fillers, diluents, hydrotropies, surface-active agents, and encapsulating substances.
• excipients may include gelatin; carbohydrates such as dextrose, mannitol, and dextran; and antioxidants such as sodium bisulfite, acetone sodium bisulfite, sodium formaldehyde, sulfoxylate, thiourea, and EDTA.
• the pharmaceutically-acceptable excipient(s) include antimicrobial agents such as phenylmercuric nitrate, thimerosal, benzethonium chloride, benzalkonium chloride, phenol, cresol, and chlorobutanol.
• antimicrobial agents such as phenylmercuric nitrate, thimerosal, benzethonium chloride, benzalkonium chloride, phenol, cresol, and chlorobutanol.
• the pharmaceutical formulations are administered to a subject that is a mammal.
• the pharmaceutical formulations are administered to a subject that is a human.
• the compounds herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
• Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids.
• Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
• Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
• Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
• Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.
• Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
• C a to C b or “C a-b ” in which “a” and “b” are integers refer to the number of carbon atoms in the specified group. That is, the group can contain from “a” to “b”, inclusive, carbon atoms.
• a “C1 to C4 alkyl” or “C1-4 alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2CH2-, CH3CH2CH(CH3)- and (CH3)3C-.
• halogen or “halo,” as used herein, means any one of the radio- stable atoms of column 7 of the Periodic Table of the Elements, e.g., fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred.
• alkyl refers to a straight or branched hydrocarbon chain that is fully saturated (i.e., contains no double or triple bonds).
• the alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., “1 to 20 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated).
• the alkyl group may also be a medium size alkyl having 1 to 9 carbon atoms.
• the alkyl group could also be a lower alkyl having 1 to 4 carbon atoms.
• the alkyl group of the compounds may be designated as “C 1-4 alkyl” or similar designations.
• C 1-4 alkyl indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
• Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like.
• haloalkyl refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain, substituting one or more hydrogens with halogens.
• haloalkyl groups include, but are not limited to, -CF3, - CHF2, -CH2F, -CH2CF3, -CH2CHF2, -CH2CH2F, -CH2CH2Cl, -CH2CF2CF3 and other groups that in light of the ordinary skill in the art and the teachings provided herein, would be considered equivalent to any one of the foregoing examples.
• alkoxy refers to the formula –OR wherein R is an alkyl as is defined above, such as “C 1-9 alkoxy”, including but not limited to methoxy, ethoxy, n- propoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy, and the like.
• polyethylene glycol refers to the formula wherein n is an integer greater than one and R is a hydrogen or alkyl. The number of repeat units “n” may be indicated by referring to a number of members.
• “2- to 5-membered polyethylene glycol” refers to n being an integer selected from two to five.
• R is selected from methoxy, ethoxy, n-propoxy, 1- methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy.
• heteroalkyl refers to a straight or branched hydrocarbon chain containing one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur, in the chain backbone.
• the heteroalkyl group may have 1 to 20 carbon atoms although the present definition also covers the occurrence of the term “heteroalkyl” where no numerical range is designated.
• the heteroalkyl group may also be a medium size heteroalkyl having 1 to 9 carbon atoms.
• the heteroalkyl group could also be a lower heteroalkyl having 1 to 4 carbon atoms.
• the heteroalkyl may have from 1 to 4 heteroatoms, from 1 to 3 heteroatoms, 1 or 2 heteroatoms, or 1 heteroatom.
• the heteroalkyl group of the compounds may be designated as “C1-4 heteroalkyl” or similar designations.
• the heteroalkyl group may contain one or more heteroatoms.
• C1-4 heteroalkyl indicates that there are one to four carbon atoms in the heteroalkyl chain and additionally one or more heteroatoms in the backbone of the chain.
• aromatic refers to a ring or ring system having a conjugated pi electron system and includes both carbocyclic aromatic (e.g., phenyl) and heterocyclic aromatic groups (e.g., pyridine).
• the term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of atoms) groups provided that the entire ring system is aromatic.
• aryl refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent carbon atoms) containing only carbon in the ring backbone. When the aryl is a ring system, every ring in the system is aromatic.
• the aryl group may have 6 to 18 carbon atoms, although the present definition also covers the occurrence of the term “aryl” where no numerical range is designated. In some embodiments, the aryl group has 6 to 10 carbon atoms.
• the aryl group may be designated as “C 6-10 aryl,” “C6 or C10 aryl,” or similar designations.
• aryl groups include, but are not limited to, phenyl, naphthyl, azulenyl, and anthracenyl.
• aryloxy and arylthio refers to RO- and RS-, in which R is an aryl as is defined above, such as “C 6-10 aryloxy” or “C 6-10 arylthio” and the like, including but not limited to phenyloxy.
• an “aralkyl” or “arylalkyl” is an aryl group connected, as a substituent, via an alkylene group, such “C 7-14 aralkyl” and the like, including but not limited to benzyl, 2-phenylethyl, 3-phenylpropyl, and naphthylalkyl.
• the alkylene group is a lower alkylene group (i.e., a C 1-4 alkylene group).
• heteroaryl refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent atoms) that contain(s) one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur, in the ring backbone.
• heteroaryl is a ring system, every ring in the system is aromatic.
• the heteroaryl group may have 5-18 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term “heteroaryl” where no numerical range is designated.
• the heteroaryl group has 5 to 10 ring members or 5 to 7 ring members.
• the heteroaryl group may be designated as “5-7 membered heteroaryl,” “5-10 membered heteroaryl,” or similar designations.
• a heteroaryl contains from 1 to 4 heteroatoms, from 1 to 3 heteroatoms, from 1 to 2 heteroatoms, or 1 heteroatom.
• a heteroaryl contains 1 to 4 nitrogen atoms, 1 to 3 nitrogen atoms, 1 to 2 nitrogen atoms, 2 nitrogen atoms and 1 sulfur or oxygen atom, 1 nitrogen atom and 1 sulfur or oxygen atom, or 1 sulfur or oxygen atom.
• heteroaryl rings include, but are not limited to, furyl, thienyl, phthalazinyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolinyl, isoquinlinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolyl, and benzothienyl.
• a “heteroaralkyl” or “heteroarylalkyl” is heteroaryl group connected, as a substituent, via an alkylene group. Examples include but are not limited to 2-thienylmethyl, 3-thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazollylalkyl, and imidazolylalkyl.
• the alkylene group is a lower alkylene group (i.e., a C1-4 alkylene group).
• carbocyclyl means a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system backbone. When the carbocyclyl is a ring system, two or more rings may be joined together in a fused, bridged or spiro-connected fashion. Carbocyclyls may have any degree of saturation provided that at least one ring in a ring system is not aromatic. Thus, carbocyclyls include cycloalkyls, cycloalkenyls, and cycloalkynyls.
• the carbocyclyl group may have 3 to 20 carbon atoms, although the present definition also covers the occurrence of the term “carbocyclyl” where no numerical range is designated.
• the carbocyclyl group may also be a medium size carbocyclyl having 3 to 10 carbon atoms.
• the carbocyclyl group could also be a carbocyclyl having 3 to 6 carbon atoms.
• the carbocyclyl group may be designated as “C3-6 carbocyclyl” or similar designations.
• carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3-dihydro-indene, bicycle[2.2.2]octanyl, adamantyl, and spiro[4.4]nonanyl.
• a “(carbocyclyl)alkyl” is a carbocyclyl group connected, as a substituent, via an alkylene group, such as “C 4-10 (carbocyclyl)alkyl” and the like, including but not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like.
• the alkylene group is a lower alkylene group.
• cycloalkyl means a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
• cycloalkenyl means a carbocyclyl ring or ring system having at least one double bond, wherein no ring in the ring system is aromatic. An example is cyclohexenyl.
• heterocyclyl means a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. Heterocyclyls may be joined together in a fused, bridged or spiro-connected fashion. Heterocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. The heteroatom(s) may be present in either a non-aromatic or aromatic ring in the ring system.
• the heterocyclyl group may have 3 to 20 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term “heterocyclyl” where no numerical range is designated.
• the heterocyclyl group may also be a medium size heterocyclyl having 3 to 10 ring members.
• the heterocyclyl group could also be a heterocyclyl having 3 to 6 ring members.
• the heterocyclyl group may be designated as “3-6 membered heterocyclyl” or similar designations.
• a heterocyclyl contains from 1 to 4 heteroatoms, from 1 to 3 heteroatoms, from 1 to 2 heteroatoms, or 1 heteroatom.
• a heterocyclyl contains 1 to 4 nitrogen atoms, 1 to 3 nitrogen atoms, 1 to 2 nitrogen atoms, 2 nitrogen atoms and 1 sulfur or oxygen atom, 1 nitrogen atom and 1 sulfur or oxygen atom, or 1 sulfur or oxygen atom.
• the heteroatom(s) are selected from one up to three of O, N or S, and in preferred five membered monocyclic heterocyclyls, the heteroatom(s) are selected from one or two heteroatoms selected from O, N, or S.
• heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1,3-dioxanyl, 1,4-dioxinyl, 1,4-dioxanyl, 1,3-oxathianyl, 1,4- oxathiinyl, 1,4-oxathianyl, 2H-1,2-oxazinyl, trioxanyl, hexa
• a “(heterocyclyl)alkyl” is a heterocyclyl group connected, as a substituent, via an alkylene group. Examples include, but are not limited to, imidazolinylmethyl and indolinylethyl.
• Non-limiting examples include formyl, acetyl, propanoyl, benzoyl, and acryl.
• a “cyano” group refers to a “-CN” group.
• a “cyanato” group refers to an “-OCN” group.
• An “isocyanato” group refers to a “-NCO” group.
• a “thiocyanato” group refers to a “-SCN” group.
• An “isothiocyanato” group refers to an “ -NCS” group.
• a “sulfonyl” group refers to an “-SO2R” group in which R is selected from hydrogen, C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• S-sulfonamido refers to a “-SO 2 NR A R B ” group in which R A and RB are each independently selected from hydrogen, C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• N-sulfonamido refers to a “-N(RA)SO2RB” group in which RA and Rb are each independently selected from hydrogen, C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 3-7 carbocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• An “amino” group refers to a “-NRARB” group in which RA and RB are each independently selected from hydrogen, C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 carbocyclyl, C 6-10 aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• An “aminoalkyl” group refers to an amino group connected via an alkylene group.
• An “alkoxyalkyl” group refers to an alkoxy group connected via an alkylene group, such as a “C 2-8 alkoxyalkyl” and the like.
• a “natural amino acid side chain” refers to the side-chain substituent of a naturally occuring amino acid. Naturally occurring amino acids have a substituent attached to the ⁇ –carbon. Naturally occurring amino acids include Arginine, Lysine, Aspartic acid, Glutamic acid, Glutamine, Asparagine, Histidine, Serine, Threonine, Tyrosine, Cysteine, Methionine, Tryptophan, Alanine, Isoleucine, Leucine, Phenylalanine, Valine, Proline, and Glycine.
• a “non-natural amino acid side chain” refers to the side- chain substituent of a non-naturally occurring amino acid.
• Non-natural amino acids include ⁇ -amino acids ( ⁇ 3 and ⁇ 2 ), Homo-amino acids, Proline and Pyruvic acid derivatives, 3- substituted Alanine derivatives, Glycine derivatives, Ring-substituted Phenylalanine and Tyrosine Derivatives, Linear core amino acids and N-methyl amino acids.
• Exemplary non- natural amino acids are available from Sigma-Aldridge, listed under “unnatural amino acids & derivatives.” See also, Travis S. Young and Peter G. Schultz, “Beyond the Canonical 20 Amino Acids: Expanding the Genetic Lexicon,” J. Biol. Chem. 2010 285: 11039-11044, which is incorporated by reference in its entirety.
• a substituted group is derived from the unsubstituted parent group in which there has been an exchange of one or more hydrogen atoms for another atom or group.
• substituted it is meant that the group is substituted with one or more subsitutents independently selected from C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 heteroalkyl, C3-C7 carbocyclyl (optionally substituted with halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, and C 1 -C 6 haloalkoxy), C3- C 7 -carbocyclyl-C 1 -C 6 -alkyl (optionally substituted with halo, C 1 -C 6 alkyl, C 1 -C 6 al
• substituted group(s) is (are) substituted with one or more substituent(s) individually and independently selected from C 1 -C 4 alkyl, amino, hydroxy, and halogen.
• substituent(s) individually and independently selected from C 1 -C 4 alkyl, amino, hydroxy, and halogen.
• certain radical naming conventions can include either a mono-radical or a di-radical, depending on the context. For example, where a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a di-radical.
• a substituent identified as alkyl that requires two points of attachment includes di-radicals such as –CH 2 –, –CH 2 CH 2 –, –CH 2 CH(CH 3 )CH 2 –, and the like.
• Other radical naming conventions clearly indicate that the radical is a di-radical such as “alkylene” or “alkenylene.”
• each R group is not otherwise limited by the definition of each R group when taken individually.
• R 1 and R 2 are defined as selected from the group consisting of hydrogen and alkyl, or R 1 and R 2 together with the nitrogen to which they are attached form a heterocyclyl
• R 1 and R 2 can be selected from hydrogen or alkyl, or alternatively, the substructure has structure: where ring A is a heterocyclyl ring containing the depicted nitrogen.
• two “adjacent” R groups are said to form a ring “together with the atoms to which they are attached,” it is meant that the collective unit of the atoms, intervening bonds, and the two R groups are the recited ring.
• R 1 and R 2 are defined as selected from the group consisting of hydrogen and alkyl, or R 1 and R 2 together with the atoms to which they are attached form an aryl or carbocyclyl
• R 1 and R 2 can be selected from hydrogen or alkyl
• the substructure has structure: where A is an aryl ring or a carbocyclyl containing the depicted double bond.
• a substituent is depicted as a di-radical (i.e., has two points of attachment to the rest of the molecule), it is to be understood that the substituent can be attached in any directional configuration unless otherwise indicated.
• the term “mammal” is used in its usual biological sense. Thus, it specifically includes, but is not limited to, primates, including simians (chimpanzees, apes, monkeys) and humans, cattle, horses, sheep, goats, swine, rabbits, dogs, cats, rats and mice but also includes many other species.
• Subject as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate.
• An “effective amount” or a “therapeutically effective amount” as used herein refers to an amount of a therapeutic agent that is effective to relieve, to some extent, or to reduce the likelihood of onset of, one or more of the symptoms of a disease or condition, and includes curing a disease or condition.
• “Curing” means that the symptoms of a disease or condition are eliminated; however, certain long-term or permanent effects may exist even after a cure is obtained (such as extensive tissue damage).
• “Treat,” “treatment,” or “treating,” as used herein refers to administering a pharmaceutical composition for prophylactic and/or therapeutic purposes.
• prophylactic treatment refers to treating a subject who does not yet exhibit symptoms of a disease or condition, but who is susceptible to, or otherwise at risk of, a particular disease or condition, whereby the treatment reduces the likelihood that the patient will develop the disease or condition.
• therapeutic treatment refers to administering treatment to a subject already suffering from a disease or condition.
• the compounds disclosed herein may be synthesized by methods described below, or by modification of these methods. Ways of modifying the methodology include, among others, temperature, solvent, reagents etc., known to those skilled in the art.
• Ways of modifying the methodology include, among others, temperature, solvent, reagents etc., known to those skilled in the art.
• it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry (ed. J.F.W. McOmie, Plenum Press, 1973); and P.G.M. Green, T.W.
• the compounds of the present technology contain one or more chiral centers, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or d(l) stereoisomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of the present technology, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like.
• the starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof.
• many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California , USA), Emka-Chemce or Sigma (St. Louis, Missouri, USA).
• the methods disclosed herein may include constructing a 39-amino acid peptide backbone using solid-phase peptide synthesis techniques to provide intermediate (II).
• the peptide backbone includes two PEG2 amide linkers.
• the method includes an amide coupling reaction between the amine of the terminal PEG2 amide of intermediate (II) and an appropriately substituted carboxylic acid (III) to provide the resin-bound intermediate (IV).
• the method involves subjecting intermediate (IV) to hydrolysis under acidic conditions followed by purification to yield the final product (I). (Scheme 1).
• the pharmaceutical formulations can be prepared as unit dosage forms. Techniques and compositions for preparing unit dosage forms are described in: Modern Pharmaceutics, 4th Ed., Chapters 9 and 10 (Banker & Rhodes, editors, 2002); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1989); and Ansel, Introduction to Pharmaceutical Dosage Forms 8th Edition (2004), each of which is incorporated herein by reference in its entirety.
• the pharmaceutical formulations disclosed herein include compounds or their tautomers and/or pharmaceutically acceptable salts thereof that can effectively act as GIP/GLP1 dual receptor agonists.
• the pharmaceutical formulations further comprise one or more pharmaceutically acceptable carriers and one or more pharmaceutically acceptable diluents.
• Some embodiments provide a method of preventing, treating, or ameliorating one or more fatty liver diseases in a subject. In some embodiments, the method includes administering one or more of the pharmaceutical formulations disclosed herein to a subject in need thereof.
• Some embodiments provide a method preventing, treating, or ameliorating steatosis, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
• the method includes administering one or more of the pharmaceutical formulations disclosed herein to a subject in need thereof.
• the method of administering one or more of the pharmaceutical formulations disclosed herein results in the prevention, treatment, or amelioration, of a fibrosis, fibrotic condition, or fibrotic symptoms.
• the pharmaceutical formulations described herein can be used to treat a host of conditions arising from fibrosis or inflammation, and specifically including those associated with myofibroblast differentiation.
• Exemplary conditions include but are not limited to progressive liver fibrosis (alcoholic, viral, autoimmune, metabolic and hereditary chronic disease), renal fibrosis (e.g., resulting from chronic inflammation, infections or type II diabetes), lung fibrosis (idiopathic or resulting from environmental insults including toxic particles, sarcoidosis, asbestosis, hypersensitivity pneumonitis, bacterial infections including tuberculosis, medicines, etc.), interstitial fibrosis, systemic scleroderma (autoimmune disease in which many organs become fibrotic), macular degeneration (fibrotic disease of the eye), pancreatic fibrosis (resulting from, for example, alcohol abuse and chronic inflammatory disease of the pancreas), fibrosis of the spleen (from sickle cell anemia, other blood disorders), cardiac fibrosis (resulting from infection, inflammation and hypertrophy), mediastinal fibrosis, myelofibrosis, endomyocardial fibrosis, retroperitoneal fibrosis, progressive massive
• the method of administering one or more of the pharmaceutical formulations disclosed herein results in the reduction in the amount of extracellular matrix proteins present in one or more tissues of said subject.
• the method of administering one or more of the pharmaceutical formulations disclosed herein results in the reduction in the amount of collagen present in one or more tissues of said subject.
• the method of administering one or more of the pharmaceutical formulations disclosed herein results in the reduction in the amount of Type I, Type Ia, or Type III collagen present in one or more tissues of said subject.
• Some embodiments provide a method of preventing, treating, or ameliorating one or more of liver fibrosis, renal fibrosis, biliary fibrosis, pancreatic fibrosis, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis, primary biliary cirrhosis, or idiopathic fibrosis in a subject.
• the method includes administering one or more of the pharmaceutical formulations disclosed herein to a subject in need thereof.
• Some embodiments provide a method of preventing, treating, or ameliorating one or more of nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis, or primary biliary cirrhosis in a subject.
• the method includes administering one or more of the pharmaceutical formulations disclosed herein to a subject in need thereof.
• Some embodiments provide a method of preventing, treating, or ameliorating one or more metabolic disorders or metabolic syndromes.
• said disease or disorder is atherosclerosis, diabetes, hyperglycemic diabetes, type 2 diabetes mellitus, dyslipidemia, hypercholesterolemia, hyperlipidemia, hypertension, hypoglycemia, obesity, or prader-willi syndrome.
• the method includes administering one or more of the pharmaceutical formulations disclosed herein to a subject in need thereof. [0117] In some embodiments, the method of administering one or more of the pharmaceutical formulations disclosed herein results in the activation of a glucose-dependent insulinotropic polypeptide (GIP) receptor. In some embodiments, the method of administering one or more of the pharmaceutical formulations disclosed herein results in the activation of a glucagon-like peptide-1 (GLP-1) receptor.
• GIP glucose-dependent insulinotropic polypeptide
• GLP-1 glucagon-like peptide-1
• the method of administering one or more of the pharmaceutical formulations disclosed herein results in the activation of the GIP receptor and the GLP-1 receptor.
• Some embodiments include co-administering a pharmaceutical formulation and/or a compound, or pharmaceutically acceptable salt thereof, described herein, with an additional medicament.
• co-administration it is meant that the two or more agents may be found in the patient’s bloodstream at the same time, regardless of when or how they are actually administered.
• the agents are administered simultaneously.
• administration in combination is accomplished by combining the agents in a single dosage form.
• the agents are administered sequentially.
• the agents are administered through the same route, such as orally.
• the agents are administered through different routes, such as one being administered subcutaneously, another being administered orally and another being administered i.v.
• routes such as one being administered subcutaneously, another being administered orally and another being administered i.v.
• the resulting bromo alkene is hydrogenated, and treated with dibenzyl phosphite in weak base to form a phosphonate ester. Hydrolysis of the methyl carboxylate provides desired INT 1 having a terminal carboxylic acid and a dibenzyl phosphonate.
• EXAMPLE 2 Synthesis of Common Peptide Backbone [0133]
• the 39-amino acid peptide backbone is constructed using solid-phase peptide synthesis techniques with diimide, HATU, or HBTU activation for amide linkage synthesis on a Rink resin. Reagent selection varies based on the identity of the amino acids being connected.
• the R-group of lysine-19 was extended with two PEG 2 amide linkers.
• the entire backbone is synthesized on the resin before coupling INT 4, INT 5, or INT 6 to the amino terminus of the lysine-bound linker.
• EXAMPLE 3 Synthesis of Compound 4 [0134]
• the peptide backbone is coupled to INT 4 to give resin-bound, protected Compound 4.
• the ratio of compound-receptor binding with 2% HSA to compound-receptor binding with 0% HSA is listed in Table 2.
• Tirzepatide has an HSA ratio of 12.8 and 5.82 for the GLP-1 receptor and GIP receptor, respectively.
• Compound 4 has an HSA ratio of 6.42 and 1.25 for the GLP-1 receptor and GIP receptor, respectively.
• the larger HSA ratios of tirzepatide when compared to Compound 4 indicates that the binding affinity of tirzepatide for albumin is greater than that of Compound 4.
• Table 2 [0140] In previous studies, a direct correlation between albumin binding affinity and in vivo half life was observed; compounds having a longer half life displayed greater albumin binding affinity. (Lau, J., et al. J. Med. Chem.
• the binding affinity of tirzepatide for albumin is greater than that of Compound 4.
• the pharmacokinetic experiments described in this example determined the half life of tirzepatide and Compound 4 to be 66.2 h and 106 h, respectively, in Formulation 1.
• the half life of tirzepatide and Compound 4 were determined to be 59.8 h and 120 h, respectively, in Formulation 2.
• the longer half life of Compound 4 in Formulation 1 and Formulation 2 when compared to that of tirzepatide is an unexpected result in view of the previous studies.
• the smaller HSA ratio of Compound 4 indicates that Compound 4 would be expected to have lower albumin binding affinity and shorter half life relative to tirzepatide.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Zoology (AREA)
• Biochemistry (AREA)
• Endocrinology (AREA)
• Genetics & Genomics (AREA)
• Immunology (AREA)
• Toxicology (AREA)
• Dermatology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=87348890

Family Applications (1)

Country Status (11)

Cited By (3)

Citations (2)

Family Cites Families (3)

• 2023
  • 2023-01-11 CN CN202380028118.2A patent/CN118946368A/zh active Pending
  • 2023-01-11 AU AU2023208627A patent/AU2023208627A1/en active Pending
  • 2023-01-11 JP JP2024542372A patent/JP2025502383A/ja active Pending
  • 2023-01-11 US US18/729,459 patent/US20250171499A1/en active Pending
  • 2023-01-11 CA CA3248728A patent/CA3248728A1/en active Pending
  • 2023-01-11 MX MX2024008795A patent/MX2024008795A/es unknown
  • 2023-01-11 KR KR1020247027089A patent/KR20240136386A/ko active Pending
  • 2023-01-11 EP EP23743616.7A patent/EP4466022A4/en active Pending
  • 2023-01-11 WO PCT/US2023/010565 patent/WO2023141044A1/en not_active Ceased
  • 2023-01-17 TW TW112101927A patent/TW202339789A/zh unknown
  • 2023-01-18 AR ARP230100109A patent/AR128285A1/es unknown

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events